Assessing Hibiscus rosa-sinensis Linn as an Excipient in Sustained-Release Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Assessing Hibiscus rosa-sinensis Linn as an Excipient in Sustained-Release Tablets
Natural gums and mucilage are biocompatible, cheap, readily available, and represent a potential source of excipients. The authors examine the functionality of mucilage extracted from the leaves of Hibiscus rosa-sinensis Linn as an excipient in a sustained-release tablet formulation.


Pharmaceutical Technology
Volume 32, Issue 1

15. P. Santiago et al. "Design of Peumus boldus Tablets by Direct Compression Using a Novel Dry Plant Extract," Int. J. Pharm. 233 (1–2), 191–198 (2002).

16. C.W. Vendruscolo et al, "Xanthan and Galactomannan (from M. scabrella) Matrix Tablets for Oral Controlled Delivery of Theophylline," Int. J. Pharm. 296 (1–2), 1–11 (2005).

17. F. Ughini et al., "Evaluation of Xanthan and Highly Substituted Galactomannan from M. scabrella as a Sustained Release Matrix," Int. J. Pharm. 271 (1–2), 197–205 (2004).

18. U. Melike and A. Turan, "Evaluation of Honey Locust (Gleditsia triacanthos Linn) Gum as a Sustaining Material in Tablet Dosage Form," IL Farmaco 59 (7), 567–573 (2004).

19. P.D. Bharadia et al., "A Preliminary Investigation on Sesbania Gum as a Pharmaceutical Excipient," Int. J. Pharma. Excip. 1 (4) 99–102 (2004).

20. S.K. Baveja, K.V. Rao, and J. Arora, "Examination of Natural Gums and Mucilage as Sustaining Agents in Tablet Dosage Forms," Indian J. Pharm. Sci. 50 (2), 89–92 (1988).

21. S. Sumathi and A.R. Ray, "Release Behavior of Drugs from Tamarind Seed Polysaccharide Tablets," J. Pharm. Sci. 5 (1), 12–18 (2002).

22. D.M. Morkhade et al., "Gum Copal and Gum Damar: Novel Matrix Forming Material for Sustained Drug Delivery," Ind. J. Pharm. Sci. 68 (1), 53–58 (2006).

23. J. Anjaria, M. Parabia, and S. Dwivedi, Ethnovet Heritage–Indian Ethnoveterinary Medicine an Overview. (Pathik Enterprise, Ahmedabad, India, 1st ed., 2002), p. 382.

24. I.A. Ross, Medicinal Plants of the World—Chemical Constituents, Traditional and Modern Medicine Uses (Humana Press, Totowa, NJ 1999), pp. 155-163.

25. K.R. Kirtikar and B. D. Basu, Indian Medicinal Plants (International Book Distributors, Dehradun, India, 1999), p. 335.

26. The Wealth of India, First Supplement Series (Raw Materials) (National Institute of Science and Communication, CSIR, New Delhi, India, Volume 3: D–I, 2002), pp. 386–387.

27. The Wealth of India, First Supplement Series (Raw Materials) (National Institute of Science and Communication, CSIR, New Delhi, India, Volume V: H–K, 2002), pp. 91–92.

28. J.A. Duke, and E. S. Ayensu, Medicinal Plants of China. (Reference Publication Inc., Algonac, MI 1985).

29. J.G. Hardman and L.E. Limbrid. Goodman's and Gilman's The Pharmacological Basis of Therapeutics (McGraw Hill, New York, 9th ed., 1995).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here